Cancers (Oct 2023)
Characterization of Age-Associated, Neutrophil-to-Lymphocyte Ratio (NLR) and Systemic Immune-Inflammatory Index (SII) as Biomarkers of Inflammation in Geriatric Patients with Cancer Treated with Immune Checkpoint Inhibitors: Impact on Efficacy and Survival
- Khalil Choucair,
- Caroline Nebhan,
- Alessio Cortellini,
- Stijn Hentzen,
- Yinghong Wang,
- Cynthia Liu,
- Raffaele Giusti,
- Marco Filetti,
- Paolo Antonio Ascierto,
- Vito Vanella,
- Domenico Galetta,
- Annamaria Catino,
- Nour Al-Bzour,
- Azhar Saeed,
- Ludimila Cavalcante,
- Pamela Pizzutilo,
- Carlo Genova,
- Melissa Bersanelli,
- Sebastiano Buti,
- Douglas B. Johnson,
- Claudia Angela Maria Fulgenzi,
- David J. Pinato,
- Maluki Radford,
- Chul Kim,
- Abdul Rafeh Naqash,
- Anwaar Saeed
Affiliations
- Khalil Choucair
- Barbara Ann Karmanos Cancer Institute, Department of Oncology, Wayne State University School of Medicine, Detroit, MI 48201, USA
- Caroline Nebhan
- Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, USA
- Alessio Cortellini
- Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London SW7 2BX, UK
- Stijn Hentzen
- Department of Medicine, Kansas University Medical Center, Kansas City, KS 66211, USA
- Yinghong Wang
- The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
- Cynthia Liu
- Department of Internal Medicine, Baylor College of Medicine, Houston, TX 77030, USA
- Raffaele Giusti
- Medical Oncology Unit, Azienda Ospedaliero Universitaria Sant’Andrea, 00189 Rome, Italy
- Marco Filetti
- Phase 1 Unit, Fondazione Policlinico Universitario Agostino Gemelli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 71013 Rome, Italy
- Paolo Antonio Ascierto
- Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131 Napoli, Italy
- Vito Vanella
- Istituto Nazionale Tumori IRCCS Fondazione Pascale, 80131 Napoli, Italy
- Domenico Galetta
- Medical Thoracic Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy
- Annamaria Catino
- Medical Thoracic Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy
- Nour Al-Bzour
- UPMC Hillman Cancer Center, Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh, Pittsburgh, PA 15232, USA
- Azhar Saeed
- Department of Pathology and Laboratory Medicine, University of Vermont Medical Center, Burlington, VT 05401, USA
- Ludimila Cavalcante
- Novant Health Cancer Institute, Charlotte, NC 28204, USA
- Pamela Pizzutilo
- Medical Thoracic Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy
- Carlo Genova
- UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy
- Melissa Bersanelli
- Medical Oncology Unit, University Hospital of Parma, 43125 Parma, Italy
- Sebastiano Buti
- Medicine and Surgery Department, University of Parma, 43121 Parma, Italy
- Douglas B. Johnson
- Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, USA
- Claudia Angela Maria Fulgenzi
- Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London SW7 2BX, UK
- David J. Pinato
- Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London SW7 2BX, UK
- Maluki Radford
- Department of Medicine, Kansas University Medical Center, Kansas City, KS 66211, USA
- Chul Kim
- Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20057, USA
- Abdul Rafeh Naqash
- Medical Oncology/Stephenson Cancer Center, University of Oklahoma, Oklahoma City, OK 73019, USA
- Anwaar Saeed
- UPMC Hillman Cancer Center, Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh, Pittsburgh, PA 15232, USA
- DOI
- https://doi.org/10.3390/cancers15205052
- Journal volume & issue
-
Vol. 15,
no. 20
p. 5052
Abstract
Background: Geriatric patients (≥80 years) are underrepresented in immune checkpoint inhibitor (ICIs) clinical trials. However, their unique biology may affect their response to ICIs. There are currently no established biomarkers of the response to ICIs in adult patients with cancer that can help with patient selection. Methods: We built a multicenter, international retrospective study of 885 patients (p p p p p < 0.01). Conclusion: Lower inflammation pre-ICI initiation may predict an improved response and survival in geriatric patients with cancer.
Keywords
- immune checkpoint inhibitors
- biomarkers
- geriatric oncology
- circulating inflammatory markers
- systemic immune-inflammatory index
